Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Goodbye Gleevec? Sprycel, Tasigna Vie For Front-Line CML Leadership

This article was originally published in The Pink Sheet Daily

Executive Summary

BMS' Sprycel and Novartis' Tasigna perform better on key endpoints than standard of care, Gleevec, in first-line treatment of chronic myeloid leukemia.

You may also be interested in...



Bristol's Once-daily Sprycel Faces Off Against Novartis' Tasigna After Clearance In First-line Leukemia

Tasigna sales were up by almost 100% in one quarter with first-line clearance.

Bristol's Once-daily Sprycel Faces Off Against Novartis' Tasigna After Clearance In First-line Leukemia

Tasigna sales were up by almost 100% in one quarter with first-line clearance.

Tasigna Beats Sprycel To First-Line CML Punch

Now that Novartis' Tasigna (nilotinib) has been approved by FDA for the treatment of first-line chronic myeloid leukemia, the race has officially begun for two second-generation BCR-ABL kinase inhibitors to supplant the venerable market-leader, Novartis' Gleevec (imatinib)

Related Content

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel